CRISPR-Cas9 genome-wide pooled screen for the identification of unknown glucocerebrosidase modulators

用于鉴定未知葡萄糖脑苷脂酶调节剂的 CRISPR-Cas9 全基因组合并筛选

• 批准号: 412811
• 负责人: Gilormini Pierre-Andr
• 金额: $ 9.83万
• 依托单位: Simon Fraser University (Burnaby, B.C.)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-10-01 至 2022-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=412811&lang=en
• 关键词: Activity-Based Screen; Gaucher'S Disease; Genetic Modulators; Genome-Wide Crispr Screen; Glucocerebrosidase; Parkinson'S Disease

Parkinson's disease (PD) is the second most common neurodegenerative disease, yet remarkably, no therapy exists that can slow the disease. The increasing incidence of PD makes improving our knowledge of the mechanisms and factors leading to PD of importan

帕金森病（PD）是第二常见的神经退行性疾病，然而值得注意的是，没有治疗方法可以减缓疾病。随着帕金森病发病率的不断上升，对帕金森病发病机制和发病因素的认识越来越重要，